As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

While Merck's oncology powerhouse Keytruda delivered another multibillion-dollar sales haul in the third quarter, regional ...

On Thursday, Merck & Co Inc (NYSE:MRK) reported third-quarter sales of $16.66 billion, up 4% year over year, beating the ...

Despite challenges in GARDASIL sales, Merck & Co Inc (MRK) reports robust growth in KEYTRUDA and new product launches, ...

Merck KGaA is a healthcare/pharma company that I have been covering and investing in for about 2 years at this point. Q2 2024 ...

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Merck & Company (MRK – Research Report), ...

Merck & Company ( (MRK) ) has released its Q3 earnings. Here is a breakdown of the information Merck & Company presented to its ...

data-text="Merck Announces Emerging Biotech Grant Program Winners" data-link=" Announces Emerging Biotech Grant Program ...